Nasdaq
$100.82▼ 3.97%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.99BShares out 29.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 6d agoAfter-hours26.09.12 05:134Ownership#●●●
GeneDx Holdings Corp.
Insider Katherine Stueland of GeneDx Holdings Corp. reported a change in beneficial ownership of securities as of September 9, 2026. This filing is a Form 4 document submitted to the SEC regarding executive stock transactions.…more
$100.82-3.97%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 6d agoAfter-hours26.09.12 05:104Ownership
GeneDx Holdings Corp.
Insider Kevin Feeley of GeneDx Holdings Corp. reported a change in beneficial ownership of securities as of September 9, 2026. This filing serves as the official Form 4 report submitted to the SEC regarding executive stock transactions.…more
$100.82-3.97%vs prev closeView filingShare - 9.3After-hours26.09.04 05:094Ownership
GeneDx Holdings Corp.
Insider Kevin Feeley of GeneDx Holdings Corp. reported a change in beneficial ownership of securities as of September 1, 2026. This filing is a standard disclosure of executive equity transactions and does not involve any changes to the company's capital structure or financial status.…more
$100.82-3.97%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.9Pre-market26.09.09 21:40#●●●#●●●
GeneDx Partners With Beren Therapeutics for NPC Genetic Testing Program…more
GeneDx has partnered with Beren Therapeutics to launch a no-cost genome sequencing program for patients with Niemann-Pick Disease Type C. This collaboration aims to overcome diagnostic barriers and facilitate earlier detection for children suffering from this rare neurodegenerative disorder.…more
$100.82-3.97%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.24Pre-market26.08.24 21:34
●●●●●●●● ●●●●● ●●●●●●
A new study published in Genetics in Medicine demonstrates that rapid genome sequencing significantly improves diagnostic rates and operational efficiency for pediatric inpatients. While the findings validate the company's technology, there is no immediate financial impact disclosed, leading to a neutral outlook.…more
$100.82-3.97%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report